Aimmune Therapeutics to Host Conference Call & Webcast to Discuss Second Quarter 2020 Financial Results & Recent Operational ...
July 23 2020 - 8:30AM
Business Wire
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical
company developing and commercializing treatments for potentially
life-threatening food allergies, today announced that it will host
a conference call on Thursday, July 30, 2020, at 4:30 p.m. ET to
discuss its financial results for the quarter and six months ended
June 30, 2020, and recent operational highlights.
To access the live call by phone, dial (877) 497-1438 (domestic)
or (262) 558-6296 (international) and enter the passcode 6195241.
To access a live or recorded webcast of the call, please visit the
Investor Relations section of the Aimmune Therapeutics website at
www.aimmune.com. The recorded webcast will be available for
approximately 30 days following the call.
About Aimmune
Aimmune Therapeutics, Inc. is a biopharmaceutical company
developing and commercializing treatments for potentially
life-threatening food allergies. With a mission to improve the
lives of people with food allergies, Aimmune is developing and
commercializing treatments for potentially life-threatening food
allergies. The Company’s Characterized Oral Desensitization
ImmunoTherapy (CODIT™) approach is intended to provide meaningful
levels of protection against allergic reactions resulting from
accidental exposure to food allergens by desensitizing patients
with defined, precise amounts of key allergens. Aimmune has one
FDA-approved medicine for peanut allergy and other investigational
therapies in development to treat other food allergies. For more
information, please visit www.aimmune.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200723005075/en/
Investors: DeDe Sheel (917) 834-1494
dsheel@aimmune.com
Media: Jodi Sievers (628) 250-6849
Jsievers@aimmune.com
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Jul 2023 to Jul 2024